Inhibition of proliferative and invasive capacities of breast cancer cells by arginine-glycine-aspartic acid peptide in vitro

Oncology Reports

Volumn 15, Issue 1, 2006, Pages 113-117

  Yang, Wanhua ^a   Meng, Li ^a   Wang, Hui ^a   Chen, Rui ^a   Wang, Rui ^a   Ma, Xiangyi ^a   Xu, Gang ^a   Zhou, Jianfeng ^a   Wang, Shixuan ^a   Lu, Yunping ^a   Ma, Ding ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Arg Gly Asp; Breast cancer; Integrins; Peptide; Tumor targeting

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; OLIGOPEPTIDE;

APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER INVASION; CELL PROLIFERATION; DRUG EFFECT; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; NEOPLASM INVASIVENESS; OLIGOPEPTIDES;

EID: 33644875690     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.1.113     Document Type: Article

References (25)

1. Jain RK: The next frontier of molecular medicine: delivery of therapeutics. Nat Med 4: 655-657, 1998.
2. Arap W, Pasqualini R and Ruoslahti E: Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279: 377-380, 1998. (Pubitemid 28063372)
3. Hong FD and Clayman GL: Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. Cancer Res 60: 6551-6556, 2000.
4. Laakkonen P, Akerman ME, Biliran H, et al: Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci USA 101: 9381-9386, 2004. (Pubitemid 38812883)
5. Pasqualini R, Koivunen E and Ruoslahti E: Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 15: 542-546, 1997. (Pubitemid 27251571)
6. Chen X, Sievers E and Hou Y, et al: Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia 7: 271-279, 2005. (Pubitemid 40411639)
7. Haubner R, Weber WA, Beer AJ, et al: Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [(18)F]galacto-RGD. PLoS Med 2: e70, Epub 2005.
8. Bernard B, Capello A, van Hagen M, et al: Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy. Cancer Biother Radiopharm 19: 173-180, 2004. (Pubitemid 38685115)
9. Janssen M, Frielink C, Dijkgraaf I, et al: Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. Cancer Biother Radiopharm 19: 399-404, 2004. (Pubitemid 39281331)
10. Dickerson EB, Akhtar N, Steinberg H, et al: Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin. Mol Cancer Res 2: 663-673, 2004.
11. Chen X, Plasencia C, Hou Y and Neamati N: Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem 48: 1098-1106, 2005. (Pubitemid 40270453)
12. Zitzmann S, Ehemann V and Schwab M: Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res 62: 5139-5143, 2002. (Pubitemid 35024582)
13. Hong FD and Clayman GL: Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. Cancer Res 60: 6551-6556, 2000.
14. Wong NC, Mueller BM, Barbas CF, Ruminski P, Quaranta V, Lin EC and Smith JW: Alpha(v) integrins mediate adhesion and migration of breast carcinoma cell lines. Clin Exp Metastasis 16: 50-61, 1998. (Pubitemid 28122555)
15. Vellon L, Menendez JA and Lupu R: alpha(V)beta(3) integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer. Oncogene 24: 3759-3773, 2005. (Pubitemid 40826875)
16. Wang SX, Zhou HY, Ma XY, Chen G, Lu YP, He FX and Ma D: Selection of targets locating on the surface of epithelial ovarian cancer cells by using phage peptide library. Zhonghua Fu Chan Ke Za Zhi 38: 412-414, 2003.
17. Brown CK, Modzelewski RA, Johnson CS and Wong MK: A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli peptide display library. Ann Surg Oncol 7: 743-749, 2000.
18. Ahmed N, Pansino F, Baker M, Rice G and Quinn M: Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer. J Cell Biochem 84: 675-686, 2002. (Pubitemid 34113107)
19. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA and Cheresh DA: Definition of two angiogenic pathways by distinct alpha v integrins. Science 270: 1500-1502, 1995. (Pubitemid 3005294)
20. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G and Cheresh DA: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164, 1994.
21. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH and Cheresh DA: Anti-integrin alpha(v)beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96: 1815-1822, 1995.
22. Lundberg P and Langel U: A brief introduction to cell-penetrating peptides. J Mol Recognit 16: 227-233, 2003. (Pubitemid 37231690)
23. Cruet-Hennequart S, Maubant S, Luis J, Gauduchon P, Staedel C and Dedhar S: Alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells. Oncogene 22: 1688-1702, 2003. (Pubitemid 36408184)
24. Bao W, Stromblad S: Integrin alpha(v)-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen. J Cell Biol 167: 745-756, 2004. (Pubitemid 39565154)
25. Chen J, Baskerville C, Han Q, Pan ZK and Huang S: Alpha(v) integrin, p38 mitogen-activated protein kinase, and urokinase plasminogen activator are functionally linked in invasive breast cancer cells. J Biol Chem 276: 47901-47905, 2001.